Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Cancer Research UK, London Research Institute, 44 Lincoln's Inn Fields, London WC2A 3PX, UK. julian.downward@cancer.org.uk
The RAS proteins control signalling pathways that are key regulators of several aspects of normal cell growth and malignant transformation. They are aberrant in most human tumours due to activating mutations in the RAS genes themselves or to alterations in upstream or downstream signalling components. Rational therapies that target the RAS pathways might inhibit tumour growth, survival and spread. Several of these new therapeutic agents are showing promise in the clinic and many more are being developed.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on